Former Allergan Chief David Pyott Signs on as Special Advisor to Sienna Biopharmaceuticals
Appointment Marks Pyott's Return to Dermatology and Aesthetics
WESTLAKE VILLAGE, Calif., Feb. 28, 2017 /PRNewswire/ -- Sienna Biopharmaceuticals, Inc., a privately held, clinical-stage medical dermatology and aesthetics company, is pleased to announce that David E.I. Pyott has signed on as special advisor to Sienna's CEO and Board of Directors. Dr. Pyott is well known from his tenure as chairman and chief executive officer of Allergan for 17 years. His new role is effective immediately and marks his return to dermatology and aesthetics.
"I look forward to working with David again. I know firsthand how invaluable his expertise and guidance are," said Frederick C. Beddingfield III, M.D., Ph.D., Sienna's President and Chief Executive Officer, who served as Vice President and Therapeutic Area Head of Dermatology and Aesthetics at Allergan and Chief Medical Officer of Allergan Medical during Dr. Pyott's tenure. "David's successful track-record building an industry-leading, diversified dermatology, ophthalmology and aesthetics company, combined with his focus on the patient and their needs, make him the perfect partner as Sienna continues to grow."
"Frederick and his experienced team have an impressive pipeline and a clear vision – to improve patients' lives by developing potentially game-changing and highly effective topical therapies that target the skin, yet have limited systemic exposure," said Dr. Pyott. "I am excited to work alongside them to address dermatologic diseases and their manifestations, as well as aesthetic concerns that are inadequately addressed by current therapies."
From 1998 to 2015, Dr. Pyott served as chief executive officer of Allergan, where he was recognized by the Harvard Business Review as one of "The 100 Best Performing CEOs in the World." Under his leadership, Allergan was transformed from a small eye care business with approximately $1 billion in sales to a global specialty pharmaceutical and medical device company, with sales of more than $7 billion in 2014 and more than 10,000 employees.
Prior to Allergan, Dr. Pyott served as the head of the Novartis Nutrition Division and as a member of the executive committee of Switzerland-based Novartis AG. Dr. Pyott is a member of the board of directors of Avery Dennison Corporation, BioMarin Pharmaceutical and Alnylam Pharmaceuticals, and a member of the supervisory board of Royal Philips in the Netherlands. He is a member of the governing board of the London Business School, president of the International Council of Ophthalmology Foundation, and a member of the advisory board of the Foundation of the American Academy of Ophthalmology. Dr. Pyott holds a diploma in International and European Law from the Europa Institute at the University of Amsterdam, a Master of Arts degree and an honorary degree in Medicine from the University of Edinburgh, and a Master of Business Administration degree from the London Business School.
About Sienna Biopharmaceuticals, Inc.
Sienna Biopharmaceuticals, Inc. is a medical dermatology and aesthetics company focused on developing safe and effective targeted therapies to treat inflammatory skin conditions and aesthetic concerns that impact the health and appearance of patients. Sienna is led by a team of accomplished scientists, clinicians and business leaders who have developed and commercialized leading global brands in dermatology and aesthetics. Sienna is building an innovative, diversified pipeline to address unmet needs in medical dermatology and aesthetics. The company's investors include: ARCH Venture Partners; Partner Fund Management; Altitude Life Science Ventures; Venvest Capital; Two River; and several prominent medical dermatology and aesthetics industry luminaries. Find more information at www.siennabio.com.
Ryan Irvine, Ph.D.
Vice President, Head of Medical Affairs
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/former-allergan-chief-david-pyott-signs-on-as-special-advisor-to-sienna-biopharmaceuticals-300414883.html
SOURCE Sienna Biopharmaceuticals, Inc.